keyword
MENU ▼
Read by QxMD icon Read
search

Leptomeningeal carcinomatosis

keyword
https://www.readbyqxmd.com/read/27914156/-intratechal-chemotherapy-treatment-through-an-ommaya-reservoir-catheter-for-meningeal-carcinomatosis-a-single-centre-experience
#1
José Pedro Lavrador, Nuno Simas, Edson Oliveira, Manuel Herculano Carvalho
INTRODUCTION: Meningeal carcinomatosis is defined as tumour cells infiltration of leptomeninges and subarachnoid space. It is normally related with poor survival (2 - 5 months). The best multidisciplinary treatment for this condition is a matter of discussion. Patient's condition and the natural history of the disease should be considered in the decision making process. MATERIAL AND METHODS: Retrospective cohort analysis of patients submitted to Ommaya Reservoir placement due to systemic solid tumour meningeal carcinomatosis between 2006 and 2014...
August 2016: Acta Médica Portuguesa
https://www.readbyqxmd.com/read/27854097/optimizing-the-delivery-of-antineoplastic-therapies-to-the-central-nervous-system
#2
REVIEW
Jarushka Naidoo, Hardik Panday, Sadhana Jackson, Stuart A Grossman
Despite significant advances in the treatment of systemic cancers, progress in the treatment of primary brain tumors has been quite modest. In addition, an increasing proportion of patients with systemic cancers are presenting with brain-only metastases. These observations highlight the critical role that the blood-brain barrier plays in preventing antineoplastic therapies from reaching the central nervous system in therapeutic concentrations. This review describes the anatomy of the blood-brain barrier and currently available methods to quantify the entry of therapeutic compounds into the brain...
November 15, 2016: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/27847569/retrospective-analysis-of-cerebrospinal-fluid-profiles-in-228-patients-with-leptomeningeal-carcinomatosis-differences-according-to-the-sampling-site-symptoms-and-systemic-factors
#3
Youngbo Shim, Ho-Shin Gwak, Sohee Kim, Jungnam Joo, Sang-Hoon Shin, Heon Yoo
OBJECTIVE: Elevated cell counts and protein levels in cerebrospinal fluid (CSF) result from disease activity in patients with leptomeningeal carcinomatosis (LMC). Previous studies evaluated the use of CSF profiles to monitor a treatment response or predict prognosis. CSF profiles vary, however, according to the sampling site and the patient's systemic condition. We compared lumbar and ventricular CSF profiles collected before intraventricular chemotherapy for LMC and evaluated the association of these profiles with patients' systemic factors and LMC disease activity...
November 2016: Journal of Korean Neurosurgical Society
https://www.readbyqxmd.com/read/27817234/-effective-systemic-palliative-chemotherapy-for-intracranial-metastases-of-breast-cancer
#4
István Sipőcz, Tamás Pintér, Zoltán Skaliczky, Tamás Kullmann
The authors present the history of two patients. The first patient, a 69-year-old woman was diagnosed with locally invasive triple negative breast cancer with pulmonary and cerebral metastases. Complete radiological remission of the clinically asymptomatic cerebral metastases was detected under systemic chemotherapy with carboplatin-docetaxel (75 mg/m(2)). Later, the patient received whole brain radiotherapy and a second line of chemotherapy. The overall survival was 20 months from the diagnosis of cerebral metastases with conservation of partial autonomy...
November 2016: Orvosi Hetilap
https://www.readbyqxmd.com/read/27809457/effects-of-postoperative-radiotherapy-on-leptomeningeal-carcinomatosis-or-dural-metastasis-after-resection-of-brain-metastases-in-breast-cancer-patients
#5
Boram Ha, Seung Yeun Chung, Yeon-Joo Kim, Ho-Shin Gwak, Jong Hee Chang, Sang Hyun Lee, In Hae Park, Keun Seok Lee, Seeyoun Lee, Tae Hyun Kim, Dae Yong Kim, Seok-Gu Kang, Chang-Ok Suh
Purpose: In this retrospective study, we compared the incidence of leptomeningeal carcinomatosis or dural metastasis (LMCDM) in patients who received whole brain radiotherapy (WBRT), partial radiotherapy (PRT), or no radiotherapy (RT) following resection of brain metastases from breast cancer. Materials and Methods: Fifty-one patients with breast cancer underwent surgical resection for newly diagnosed brain metastases in two institutions between March 2001 and March 2015...
October 31, 2016: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/27790117/rapid-response-to-high-dose-pulsatile-erlotinib-in-afatinib-refractory-leptomeningeal-carcinomatosis-from-adenocarcinoma-of-the-lung-a-case-report
#6
Frank S Fan
Leptomeningeal carcinomatosis occurred in an old female patient who was on a standard dose of afatinib for the treatment of her non-small cell lung cancer harboring an epidermal growth factor receptor gene mutation sensitive to tyrosine kinase inhibitors when extracranial lesions were still under control. Shifting to high-dose, pulsatile erlotinib dramatically saved her from the devastating condition in a very short period of time. Inadequate afatinib concentration in cerebrospinal fluid is reasonably suspected, and there is a call for clinical trials testing high-dose afatinib in leptomeningeal carcinomatosis...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27721269/prolonged-overall-survival-of-patients-with-leptomeningeal-carcinomatosis-from-nonsmall-cell-lung-cancer
#7
Yanfang Ju, Shengjie Sun, Jinliang Wang, Shunchang Jiao
Leptomeningeal metastasis (LM) carries a devastating prognosis. Treatment selection is limited for patients with LM. We introduced to use nimotuzumab (also known as h-R3) for treating LM of nonsmall cell lung cancer. Here, we report two patients in our treatment who had prolonged overall survival over 1 year each. The pressure of cerebrospinal fluid of the patients decreased remarkably after intrathecal therapy. Symptoms of the patients had been improved quickly after one or two times of intrathecal therapy...
October 2016: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/27688614/intrathecal-trastuzumab-for-leptomeningeal-carcinomatosis-in-patients-with-human-epidermal-growth-factor-receptor-2-positive-breast-cancer
#8
Seema Gulia, Sudeep Gupta, Ashish Singh
There has been recent increase in incidence of leptomeningeal carcinomatosis, possibly due to widespread use of adjuvant trastuzumab and its known poor CNS penetration. Currently there are limited therapeutic options for these patients and outcome is poor. We report two cases of women with HER2 positive breast cancer who developed leptomeningeal carcinomatosis for which they were treated with intrathecal trastuzumab in combination with systemic therapy. Both patients had rapid symptomatic benefit and radiological response and remained progression free for at least seven months...
July 2016: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/27672788/poster-21-leptomeningeal-carcinomatosis-presenting-as-tetraparesis-a-very-rare-case-of-small-cell-prostate-carcinoma
#9
Sean Bemanian, Viswanath Aluru, Pouyan Gohari, Marc Ross
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
https://www.readbyqxmd.com/read/27617103/leptomeningeal-carcinomatosis-in-non-small-cell-lung-cancer-initial-response-to-erlotinib-followed-by-relapse-despite-continuing-radiological-resolution-of-disease
#10
Alvin J X Lee, Rachel Benamore, Monika Hofer, Meenali Chitnis
A 60-year-old male was diagnosed with T3, N3, M1b epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma. Five months later he developed significant headaches, weakness and numbness of the left leg, and unsteadiness of gait. Magnetic resonance imaging (MRI) brain demonstrated subtle gyral enhancement indicative of early leptomeningeal infiltration. He was commenced on second-line erlotinib which improved his lower limb symptoms. Three months later he developed increased urinary frequency and redeveloped leg symptoms...
September 2016: Oxford Medical Case Reports
https://www.readbyqxmd.com/read/27580550/promising-effects-of-afatinib-on-leptomeningeal-carcinomatosis-derived-from-erlotinib-resistant-lung-adenocarcinoma
#11
Akimasa Sekine, Terufumi Kato, Tae Iwasawa, Tomohisa Baba, Akihiro Suido, Haruyasu Sakuranaka, Masaaki Futaki, Takashi Ogura
We herein report a case of a 67-year-old woman previously treated with erlotinib for adenocarcinoma with an epidermal growth factor receptor (EGFR) mutation in exon 19, which rapidly developed to progressive symptomatic leptomeningeal carcinomatosis. The primary tumor and lung metastases also worsened and the performance status (PS) score declined to 3. With a re-biopsy from the pulmonary metastases, the T790M mutation was detected by the cobas EGFR mutation test, but not the cycleave test, although an exon 19 deletion was detected by both of the tests...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27554216/-a-case-of-isolated-leptomeningeal-carcinomatosis-from-advanced-gastric-cancer
#12
Jung Geun Ji, Joo Won Chung, Seung Woo Nam, Seung Kyu Choi, Dong Won Lee, Dae In Kim, Byung Gwan Jeon, Yun Jae Shin
Leptomeningeal carcinomatosis (LMC) is rare metastatic form of gastric cancer. Most cases are diagnosed in the final stage after multiple distant metastasis. An 84-year-old woman was admitted with melena, headache and vomiting. Esophagogastroduodenoscopy showed an ulceroinfiltrating lesion at the stomach (Borrmann class III), and biopsy revealed a signet ring cell carcinoma. The abdominal-pelvic CT showed no evidence of metastasis. A sudden decrease of consciousness was noted, but the brain CT showed no active lesion while the brain MRI revealed enhancement of leptomeninges...
August 25, 2016: Korean Journal of Gastroenterology, Taehan Sohwagi Hakhoe Chi
https://www.readbyqxmd.com/read/27553811/optimal-management-of-leptomeningeal-carcinomatosis-in-breast-cancer-patients-a-systematic-review
#13
REVIEW
Shaan Dudani, Sasha Mazzarello, John Hilton, Brian Hutton, Lisa Vandermeer, Ricardo Fernandes, Mohammed F K Ibrahim, Stephanie Smith, Habeeb Majeed, Khalid Al-Baimani, Jean-Michel Caudrelier, Risa Shorr, Mark Clemons
The incidence of leptomeningeal carcinomatosis in breast cancer patients (LC-BC) is increasing. Despite significantly affecting patient quality of life (QoL) and overall survival (OS), little is known about its optimal management. A systematic review of treatment strategies for LC-BC was performed. EMBASE, Ovid Medline, Pubmed, and the Cochrane Central Register of Controlled Trials were searched from 1946 to 2015 for trials reporting on treatments for LC-BC. All treatment modalities and study types were considered...
December 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/27446350/leptomeningeal-carcinomatosis-as-the-primary-presentation-of-relapse-in-breast-cancer
#14
Keith Sacco, Aun Muhammad, Waqar Saleem, Heba Alshaker, Leonardo Monzon, Mohammad Rafiqul Islam, Dmitri Pchejetski
Leptomeningeal metastasis (LM) is an uncommon presentation of relapse in breast cancer, which is associated with poor clinical outcomes and poor prognosis. Notably, LM most commonly occurs in breast cancer. The aim of the present review was to investigate the occurrence of LM as the primary presentation of relapse following remission in breast cancer patients and to determine whether specific histological subtypes are predisposed to meningeal metastases. In addition, the present review evaluated whether patients presenting with LM as the primary site of relapse exhibit differences in survival when compared with patients exhibiting metastasis to other sites...
August 2016: Oncology Letters
https://www.readbyqxmd.com/read/27399673/molecular-targeted-therapies-for-the-treatment-of-leptomeningeal-carcinomatosis-current-evidence-and-future-directions
#15
REVIEW
Dae-Won Lee, Kyung-Hun Lee, Jin Wook Kim, Bhumsuk Keam
Leptomeningeal carcinomatosis (LMC) is the multifocal seeding of cerebrospinal fluid and leptomeninges by malignant cells. The incidence of LMC is approximately 5% in patients with malignant tumors overall and the rate is increasing due to increasing survival time of cancer patients. Eradication of the disease is not yet possible, so the treatment goals of LMC are to improve neurologic symptoms and to prolong survival. A standard treatment for LMC has not been established due to low incidences of LMC, the rapidly progressing nature of the disease, heterogeneous populations with LMC, and a lack of randomized clinical trial results...
2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27393516/intracranial-response-to-nivolumab-in-nsclc-patients-with-untreated-or-progressing-cns-metastases
#16
Elizabeth Dudnik, Shlomit Yust-Katz, Hovav Nechushtan, Daniel A Goldstein, Alona Zer, Dov Flex, Tali Siegal, Nir Peled
Central nervous system (CNS) metastases occur in 30% of patients with advanced non-small cell lung cancer (NSCLC). Localized treatments targeting CNS metastases result in delays in systemic therapy administration and are associated with neurocognitive impairment. Nivolumab is an immune check-point inhibitor that is approved as a second-line treatment of NSCLC. Data regarding the intracranial activity of nivolumab is lacking. We retrospectively reviewed the efficacy and safety of nivolumab in five patients with advanced NSCLC and new/progressing intracranial metastases...
August 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27306442/whole-brain-radiotherapy-in-management-of-non-small-cell-lung-carcinoma-associated-leptomeningeal-carcinomatosis-evaluation-of-prognostic-factors
#17
Yurday Ozdemir, Berna Akkus Yildirim, Erkan Topkan
To assess the efficacy of whole-brain radiotherapy (WBRT) and prognostic factors in leptomeningeal carcinomatosis (LMC) of non-small-cell lung cancer (NSCLC) patients. WBRT records of 51 LMC patients confined to brain were reviewed. Eligible patients had squamous-cell carcinoma (SCC) or adenocarcinoma, and Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-3. The WBRT was either 20 or 30 Gray. The primary and secondary objectives were to determine overall survival (OS) and prognostic factors for improved treatment response, respectively...
September 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27295918/leptomeningeal-carcinomatosis-can-be-presenting-manifestation-of-breast-carcinoma
#18
Gorana Mandić Stojmenović, Aleksandra M Pavlović, Milica Skender Gazibara, Danica Grujicić, Aleksandra Radojicić, Nadezda Covicković Sternić
INTRODUCTION: Leptomeningeal carcinomatosis (LC) is a serious complication occuring in solid cancer patients with rather poor prognosis. CASE REPORT: We presented a 47-year-old woman with the 6-month history of diffuse headache, nausea and visual obscuration. Initially, clinical status and brain magnetic resonance imaging (MRI) indicated syndrome of idiopathic intracranial hypertension. Due to clinical progression and high papillary stasis, cerebrospinal fluid (CSF) examination was performed only after ventriculoperitoneal shunt was implanted...
March 2016: Vojnosanitetski Pregled. Military-medical and Pharmaceutical Review
https://www.readbyqxmd.com/read/27285292/a-rare-case-of-leptomeningeal-carcinomatosis-in-a-patient-with-uveal-melanoma-case-report-and-review-of-literature
#19
Inna V Fedorenko, Brittany Evernden, Rajappa S Kenchappa, Solmaz Sahebjam, Elena Ryzhova, John Puskas, Linda McIntosh, Gisela Caceres, Anthony Magliocco, Arnold Etame, J William Harbour, Keiran S M Smalley, Peter A Forsyth
Uveal melanoma is a rare subtype of melanoma, accounting for only 3-5% of all melanoma cases in the USA. Although fewer than 4% of uveal melanoma patients present with metastasis at diagnosis, approximately half will develop metastasis, more than 90% of which disseminate to the liver. Infrequently, a number of malignancies can lead to leptomeningeal metastases, a devastating and terminal complication. In this case report, we present an exceedingly rare case of a patient with uveal melanoma who developed leptomeningeal carcinomatosis as the sole site of metastasis...
October 2016: Melanoma Research
https://www.readbyqxmd.com/read/27265927/an-uncommon-complication-of-esophageal-cancer
#20
Sharareh Nina Akbar, David Jacob Hermel, Gustavo Alday
Esophageal cancer is one of the rarer solid tumors that metastasize to the central nervous system. We describe a case of a 57-year-old male, previously confirmed to have obstructive esophageal adenocarcinoma with local mediastinal and esophagogastric lymph node involvement undergoing chemotherapy, who presented with altered mental status, headache, nausea, 15-pound weight loss, and neck stiffness. Prior staging with an MRI of the brain and spine was unrevealing, but a lumbar puncture demonstrated adenocarcinomatous spread to the cerebrospinal fluid, consistent with leptomeningeal carcinomatosis...
April 2016: Connecticut Medicine
keyword
keyword
71957
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"